Matrix Metalloproteinase-9 Is a Marker of Heart Failure After Acute Myocardial Infarction

2006 ◽  
Vol 12 (1) ◽  
pp. 66-72 ◽  
Author(s):  
Daniel R. Wagner ◽  
Charles Delagardelle ◽  
Isabelle Ernens ◽  
Didier Rouy ◽  
Michel Vaillant ◽  
...  
2009 ◽  
Vol 42 (4-5) ◽  
pp. 342
Author(s):  
Savas Guzel ◽  
Ozden Serin ◽  
Guzin Yilmaz ◽  
Eda Celik Guzel ◽  
Guvenc Guvenen

2004 ◽  
Vol 68 (5) ◽  
pp. 451-454 ◽  
Author(s):  
Hiroshi Funayama ◽  
San-e Ishikawa ◽  
Norifumi Kubo ◽  
Takuji Katayama ◽  
Takanori Yasu ◽  
...  

Author(s):  
Xiaoying Qiao ◽  
Shreyas Bhave ◽  
Lija Swain ◽  
Elric Zweck ◽  
Lara Reyelt ◽  
...  

AbstractNew mechanistic insight into how the kidney responds to cardiac injury during acute myocardial infarction (AMI) is required. We hypothesized that AMI promotes inflammation and matrix metalloproteinase-9 (MMP9) activity in the kidney and studied the effect of initiating an Impella CP or veno-arterial extracorporeal membrane oxygenation (VA-ECMO) before coronary reperfusion during AMI. Adult male swine were subjected to coronary occlusion and either reperfusion (ischemia-reperfusion; IR) or support with either Impella or VA-ECMO before reperfusion. IR and ECMO increased while Impella reduced levels of MMP-9 in the myocardial infarct zone, circulation, and renal cortex. Compared to IR, Impella reduced myocardial infarct size and urinary KIM-1 levels, but VA-ECMO did not. IR and VA-ECMO increased pro-fibrogenic signaling via transforming growth factor-beta and endoglin in the renal cortex, but Impella did not. These findings identify that AMI increases inflammatory activity in the kidney, which may be attenuated by Impella support.


Sign in / Sign up

Export Citation Format

Share Document